A physician reported via a sales rep that an elderly male pt received solesta (dextranomer/hyaluronic acid) injection into the submucosa of the anal canal as treatment for fecal incontinence.Additional medical history and concurrent medications were not provided.On (b)(6) 2014, the pt received solesta, on an unk date the pt developed septic escherichia coli and a high fever, requiring hospitalization.Hospital course and treatment were not provided.On an unk date, the events resolved.Causality was not reported.The company assessed the events as possibly related to solesta.
|